Prediction Model for Adjuvant Radiation Therapy for Gallbladder Cancer: Not Ready to Be Used

Arroyo, Gerardo F.; Lemoine, G

doi:10.1200/jco.2008.18.2220

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A notable example is the study conducted by Wang et al, which crafted a predictive nomogram model tailored to the implementation of adjuvant radiotherapy in a cohort of 4180 GBC patients 10 . However, it's worth noting that this model lacked the inclusion of surgical margin status and detailed information about the extent of surgical resection, possibly limiting its applicability 11,12 . Given this context, the development of more comprehensive and precise nomograms holds promise in enhancing predictive accuracy for GBC patients who have undergone curative‐intent resection.…”

Section: Introductionmentioning

confidence: 99%

“… 10 However, it's worth noting that this model lacked the inclusion of surgical margin status and detailed information about the extent of surgical resection, possibly limiting its applicability. 11 , 12 Given this context, the development of more comprehensive and precise nomograms holds promise in enhancing predictive accuracy for GBC patients who have undergone curative‐intent resection.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nomograms to predict long‐term survival for patients with gallbladder carcinoma after resection

Bai,

Yang,

Qiu

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundSurgical resection remains the primary treatment option for gallbladder carcinoma (GBC). However, there is a pressing demand for prognostic tools that can refine patients' treatment choices and tailor personalized therapies accordingly.AimsThe nomograms were constructed using the data of a training cohort (n = 378) of GBC patients at Eastern Hepatobiliary Surgery Hospital (EHBH) between 2008 and 2018. The model's performance was validated in GBC patients (n = 108) at Guangzhou Centre from 2007 to 2018.Methods and resultsThe 5‐year overall survival (OS) rate in the training cohort was 24.4%. Multivariate analyses were performed using preoperative and postoperative data to identify independent predictors of OS. These predictors were then incorporated into preoperative and postoperative nomograms, respectively. The C‐index of the preoperative nomogram was 0.661 (95% CI, 0.627 to 0.694) for OS prediction and correctly delineated four subgroups (5‐year OS rates: 48.1%, 19.0%, 15.6%, and 8.1%, p < 0.001). The C‐index of the postoperative nomogram was 0.778 (95%CI, 0.756 –0.800). Furthermore, this nomogram was superior to the 8th TNM system in both C‐index and the net benefit on decision curve analysis. The results were externally validated.ConclusionThe two nomograms showed an optimally prognostic prediction in GBC patients after curative‐intent resection.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nomograms to predict long‐term survival for patients with gallbladder carcinoma after resection

Bai,

Yang,

Qiu

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

show abstract

Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base

Mantripragada

Hamid

Shafqat

et al. 2016

JNCI J Natl Cancer Inst

View full text Add to dashboard Cite

show abstract

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Javle

Hsueh

2009

J Hematol Oncol

View full text Add to dashboard Cite

We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment.Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy. The addition of bevacizumab to gemcitabine and erlotinib was not supior to gemcitabine and erlotinib for advanced disease. Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit. Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer. The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy. Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer. Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven. Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other important presentations from the 2008 ASCO annual meeting are discussed in this article.

show abstract

Prediction Model for Adjuvant Radiation Therapy for Gallbladder Cancer: Not Ready to Be Used

Cited by 4 publications

References 8 publications

Nomograms to predict long‐term survival for patients with gallbladder carcinoma after resection

Nomograms to predict long‐term survival for patients with gallbladder carcinoma after resection

Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base

Updates in Gastrointestinal Oncology – insights from the 2008 44th annual meeting of the American Society of Clinical Oncology

Contact Info

Product

Resources

About